share_log

Piper Sandler Maintains Overweight on Xeris Biopharma Holdings, Lowers Price Target to $4-Report Released on 9th Nov 2023

Benzinga ·  Nov 10, 2023 17:21

Piper Sandler analyst David Amsellem maintains Xeris Biopharma Holdings (NASDAQ:XERS) with a Overweight and lowers the price target from $5 to $4.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment